ID   FF-1
AC   CVCL_RP34
SY   FF1
DR   cancercelllines; CVCL_RP34
DR   IARC_TP53; 27014
DR   Wikidata; Q54834770
RX   PubMed=11439348;
RX   PubMed=14522906;
RX   PubMed=25675381;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=14522906).
CC   Miscellaneous: STR profile from personal communication of Marlow, Laura A.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 12
ST   D16S539: 14
ST   D18S51: 12,16
ST   D3S1358: 17,19
ST   D5S818: 11,13
ST   D7S820: 9
ST   D8S1179: 13
ST   FGA: 20
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 19-12-24; Version: 12
//
RX   PubMed=11439348; DOI=10.1038/sj.onc.1204531;
RA   Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.;
RT   "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile
RT   response to hepatocyte growth factor.";
RL   Oncogene 20:3845-3856(2001).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. 3rd;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
//